Peptides: Lab finds problems in 30% of vials tested as FDA panel eyes loosening rules

An FDA panel with industry ties is considering loosening restrictions on peptide injections as their use explodes online, despite a testing lab finding contamination, mislabelling, or dosing problems in 30% of vials analysed. Career FDA scientists have flagged safety concerns and lack of consistent data ahead of the panel's recommendation.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.